BioNTech is having its Pfizer moment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
STAT+: Prometheus team launches new startup with $400 million to tackle immune-driven disorders
What happens after you close a nearly $11 billion acquisition? Well, for Prometheus Therapeutics’ former…
STAT+: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity
I am one week away from the launch of my weekly email newsletter! It’s called…
Novo is building a really big computer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface…
STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives
Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the…
.jpg)
STAT+: FDA approves first gene therapy for a fatal neuron disease in children
The Food and Drug Administration on Tuesday approved a gene therapy for metachromatic leukodystrophy, a…
Contineum Therapeutics files for IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
I was wrong about Geron. For years, I’ve believed — and declared publicly — that…
STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty
Around this time three years ago, while most of us navigated pandemic life, real estate developers…
What happens when an approved drug doesn’t work?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And…
STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat…
Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.
LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based…
STAT+: Argenx readies another blockbuster opportunity with its antibody drug
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China
WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese…
Geron’s resurgence might have been short-lived
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his…
When did Wall Street sour on Lilly’s Alzheimer’s drug?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: First medicine developed to treat MASH expected to be approved soon
The Food and Drug Administration is expected to approve the first medicine developed specifically to…
Preventing the weaponization of AI-designed proteins
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Eli Lilly’s anti-vanity ad campaign for Oscars
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In stunning outcome, Amylyx’s ALS drug fails large clinical trial
Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any…
STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone
If you’re a drug company executive, you probably feel like you got up on the…
STAT+: Pharma giants, government spar in court over Medicare drug price negotiation
TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson and Johnson, Novartis, and…
Listen: VC turmoil, GLP-1 competition, & the war on recovery
Why are addiction treatments so hard to get? Can small companies compete in obesity? And…
Banning WuXi is more complicated than it might sound
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial
A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss…
STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
Biden to propose expanding Medicare drug price negotiation in State of the Union
WASHINGTON — President Biden wants to more than double the size of Medicare’s new drug…
STAT+: Senate panel advances bill to ban some Chinese biotechs, with Sen. Paul taking up industry’s cause
WASHINGTON — A Senate panel today passed a bill aimed at preventing certain Chinese companies…
Bayer’s not breaking up. At least not yet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Startup Alumis raises $259 million as it prepares for psoriasis trial
San Francisco startup Alumis Inc. has raised $259 million in a bid to best big…
Where’s Lilly’s Alzheimer’s approval?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Serum Institute of India wants government HPV contract
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows
Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease…
Despite good data, Ironwood’s shares plummet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships
Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching…
STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?
WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American…
Listen: Legal insider trading, booming biotech stocks, & the next GLP-1
Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy? We cover…
The next act for a biotech rainmaker
Want to stay on top of the science and politics driving biotech today? Sign up to…
This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act
Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb…
STAT+: Biotech launches with $82 million for Parkinson’s cell therapy
The dream of being able to pluck a cell therapy off of a freezer shelf…
Q&A: A biotech VC leader shares her next big bets
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners,…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
STAT+: An inside look at PIPEs, the financing trend that has biotech abuzz
Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock…
STAT+: White House to hold a listening session on reforming pharmacy benefit managers
In a bid to combat prescription drug costs, the White House will hold a listening…
Beam is trading like it’s 2021
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines
One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry. It was…